**Supplemental Material 1. Comparison among major CKD cohort studies**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **EMB000055444edd****KNOW-CKD****Phase I and II** | **EMB000055444edb****CRIC****Phase I and III** | **EMB000055444edc****CKD-JAC** |
| Nation  | Korea | USA | Japan |
| Starting recruitment (year) | Phase I: 2011Phase II: 2019 | 2001 | 2007 |
| Recruitment centers (N) | Phase I: 9 Phase II: 14 | 11 | 17 |
| Subjects enrolled (N) | Phase I: 2,238 Phase II: 1,500 (enrollment target) | 5,439 | 2,975 |
| CKD stage (non-dialysis dependent) | CKD stage 1 to 5  | CKD stage 3 to 5(eGFR 10-60 ml/min/1.73 m2) | CKD stage 3 to 5(eGFR 10-60 ml/min/1.73 m2) |
| Biosamples | Serum, plasma, urine, DNA | Plasma, urine, DNA | Plasma, urine |
| Laboratory test  | Creatinine, cystatin C, iPTH, 25OHD, 1,25OHD, troponin T, urine: creatinine, albumin, protein, and electrolyte | Iothalamate-based clearance, creatinine,   | Creatinine, cystatin C, HbA1C, iPTH, urine: creatinine, albumin, and creatinine clearance  |
| Other test  | Echocardiography, DEXA, HRQoL | ECG, echocardiography  | ABPM, HRQoL |
| Outcomes | CV event, death, eGFR, ESKD, hospitalization, HRQoL | CV event, death, eGFR, ESKD , hospitalization, HRQoL | CV event, death, eGFR, ESKD , hospitalization, HRQoL |
| Publications | 87 | 250 | 19 |

HRQoL, health-related quality of life; HbA1c, hemoglobin A1c; ECG, electrocardiogram; DEXA, dual energy x-ray absorptiometry; CV, cardiovascular; Cr, creatinine; 25(OH)D, 25-hydroxyvitamine D; 1,25(OH)D, 1,25-dihydroxyvitamin D; iPTH, intact parathyroid hormone; ESKD, end-stage kidney disease; CRIC: Chronic Renal Insufficiency Cohort; CKD-JAC: Chronic Kidney Disease Japan Cohort; KNOW-CKD : KoreaN Cohort Study for Outcomes in Patients With Chronic Kidney Disease